A pair of studies show that Zepbound can help adults with obesity and overweight achieve sustained and meaningful weight loss ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years ...

Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...

Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes ...

Long-term use of tirzepatide shows sustained and significant weight loss in adults with overweight or obesity.

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

You may know about tirzepatide, also known as Mounjaro or Zepbound, due to its popularity for those looking to lose weight or treat diabetes. Now, researchers have gotten it approved to treat sleep ...

Zepbound belongs to a class of drugs called dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist. It contains the active ingredient tirzepatide and comes ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

They're offered in several brand name forms, like Ozempic, where semaglutide is the main substance, or Zepbound, where tirzepatide is the main substance. But they do basically the same thing.

Patients with type 2 diabetes who switched to tirzepatide rather than escalating their dulaglutide dosage had greater weight ...

Adults with obesity who used medication and received guidance on resistance training and nutrition lost substantially more ...